Member Info for LlamaFarmer

What drugs act on the central nervous system?

There are many different types of drugs that work on the CNS, including anesthetics, anticonvulsants, antiemetics, antiparkinson agents, CNS stimulants, muscle relaxants, narcotic analgesics (pain relievers), nonnarcotic analgesics (such as acetaminophen and NSAIDs), and sedatives.

Wide range of products they are looking at there - Parkinsons leaps out as does Narcotic analgesics ( fentanyl etc )

Awakn is building a strong and unique portfolio of targeted novel candidates to treat both substance and behavioural addictions. Behavioural addictions have no pharmacological treatment available globally and rates of addiction are increasing at an alarming rate, while success rates in substance addiction are very low.

https://awaknlifesciences.com/awakn-successfully-completes-phase-one-of-its-drug-discovery-program

Proprietary - SVNS owns it all, SVNS purchased all of this IP from Professor Nutts company.

Awakn has completed a hit to lead program which delivered its key goals of identifying, and patenting novel chemistry scaffolds. It also established drug discovery assays with the potential to facilitate lead optimization activities. This is an essential first step on the pathway of developing new, faster acting, and safer entactogenic therapies for the market. A combination of computational screening and medicinal chemistry approaches were utilized to identify numerous chemical scaffolds via in vitro pharmacology and DMPK testing. Multiple patents have now been filed with several of these chemical scaffolds, demonstrating in vivo activity, providing an excellent starting point for lead optimisation activities.

Professor David Nutt, Awakn’s Chief Research Officer commented, “I am so pleased that this unique and innovative program has progressed so quickly. We have patented two novel molecular series that so far replicate the in-vitro effects of MDMA and which are now ready to be optimised for the next step of in-vivo studies, which are needed before proceeding into humans”.

This announcement builds on Awakn’s acquisition in March 2021 of a significant body of proprietary research from Prof. Nutt’s Equasy Enterprises, which included details of newly discovered actions of MDMA and gave Awakn an advantageous starting point for this phase of development.

Tricky,

The question is, who did they collect them in for?

They spent all day collecting them together and then sold them for a premium at 0.17

Cancelled a 30m trade, moved the price about and all they managed to shake out was 14m shares?

Was it Pamlico Shoals buying on the open?

Dug,

I was just reading the pxen telegram group ( im allowed to read but not post ) got banned for daring to suggest they might place at some stage, Mark Routh said the same in a RNS, theyd probably ban him as well ;) they are all talking/moaning about the Co asking to issue more shares - for the Directors not for placing headroom.

p.s Viura is still Kaput - lets hope they can seal the water breach and reinstate it.

Need to have some patience, let them run the test.

That said from 8 - 10 sites across the UK and the Phase2b in the USA it would be easy enough for a hostile Co to gather early doors info and try and take them out on the cheap - that's where the 1p cheeky bid springs to mind.

Looking at these trades and the cancelled large lumps, my experience of these is of someone trying to shake stock loose from the unresearched in a small profit.

Personally like Nicholas Nelson and the rest of them who have put cash in, this can fly, stay in and watch it unfold.

Go through all of these and work out the exercise price - they need multibags to get them close to being worth changing up!

Each unit is comprised of one common share in the capital of the Company (each, a “Common Share”) and three quarters (0.75) of one whole Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to acquire one Common Share at a price of $0.63 per Common Share for a period of five (5) years from the date of issuance. Gross proceeds from the Offering will be used to fund the company’s general working capital.

Are the 2 x TR1's we are outstanding still buying and this is why they don't need to file yet?

Nicholas Nelson - holder of hundreds of millions of warrants and stock, the ex Chairman and serial investor posted his the next day on the 28th May.

At 0.13p Placing price with 5.908B shares in issue the market cap was £7,680,400

at 1p with 5.908B shares in issue it will have a market cap of £ 59,080,000

At 2p with 5.908B shares market cap of £118,160,000.00

At 4p with 5.908B market cap of £236,320,000.00

The Company are self promoting that they have been told by external experts that it is worth £200m with the initial buyout payment plus future sales bonus.

Puts it in perspective that people are clapping at 0.13 up to 0.15 doesn't it?

This has got ages to run yet, literally bags to go, I reckon 1p gets hit without too many problems - £60m marketcap, that's peanuts for what they have in a hot sector with M & A crawling all over it and they have bought in Dennis Purcell to marshall their forces.

Without any disrespect to our BOD,quite the opposite in fact, we have seen what happens in Aim / small cap pharmas when pure scientists are left to run the business, there are some car crashes we've probably all invested in and out of, these people realised what they had, were sensible enough to have attracted Nicholas Nelson as the early stage investor and Chairman and left it to him to hand over to Dennis Purcell when the products were close to being rolled out into the market place to kick this up another few levels.

I believe this to be a genuinely exciting investment case for the pi, one of the few opportunities that comes along and could provide some decent rewards for the smaller investor after the heavy lifting has been done by the BOD - very unusual in the small cap market place!

This is not a long trial in terms of time it takes.

Four months

https://www.gmmh.nhs.uk/research-news/greater-manchester-mental-health-joins-largest-ever-study-of-ketamineassisted-therapy-for-alcohol-disorder-7037/

https://www.gmmh.nhs.uk/project-details/project/morekare-70/

Over the course of a one-month period, you will receive three treatments with one of two doses of ketamine; either 0.8mg/kg or 0.05mg/kg over 40 minutes given through a drip. Alongside this you will receive seven sessions of one-to-one psychological support from a therapist, in the form of either therapy or alcohol education. The ketamine dose and type of psychological support you receive will be randomly assigned by a computer. Neither you nor the site research team will know which dose/support you are given.

Who is it for?

You have been invited to take part because you have stopped, or have expressed a desire to reduce or stop, drinking alcohol. This trial aims to recruit 280 participants from approximately 10 research centres across the UK.

A few of these centres must have completed or be very close to completing their tests by now.

The company must be itching to update us with some mid term news flow?

30m trade cancelled off

Can still sell over 20m at 0.141

Dr David Nutt has synthesised Ketamine into a low doseage, thin film membrane, he has intellectual property and patents over his products which SVNS / Awakn purchased from him in exchange for stock.

What they have and the unique low doseage formula cannot be taken away from them, no one is allowed to plagerise their work for 10 years..

Ketamine users build resistance quickly, that means they require a higher doesage to reach the same 'high' i.e the actor Mathew Perry whose death was attributed to Ketamin, that is why this treatment is so important, three low dosages that can be given sublingually.

https://pubmed.ncbi.nlm.nih.gov/35899184/

Psychedelic Health

https://psychedelichealth.co.uk › 2023/01/26 › study-to...

26 Jan 2023 — The trial's participants will consist of harmful drinkers, they will be administered a dose of (S)-ketamine delivered via a proprietary oral thin film formulation.

https://www.newsfilecorp.com/release/76548/Awakn-Acquires-Proprietary-Next-Generation-MDMA-and-Ketamine-Data-from-Prof.-David-Nutt

London, United Kingdom--(Newsfile Corp. - March 9, 2021) - Awakn Life Sciences Inc., a clinical-biotech company researching, developing, and delivering psychedelic medicine to treat addiction and other mental health conditions, today announced the acquisition of significant proprietary research data on next generation candidate MDMA and Ketamine molecules from Prof. David Nutt's Equasy Enterprises. In addition to the acquisition of the data, Prof. Nutt has been appointed as Head of Research to lead Awakn's next generation psychedelic molecule development programme.

And we are still overdue two x RNS from placing increases

Https://youtu.be/PPpTymob3aw?si=1_cq3F9IUkWt4RmK

On the Morekare website there is a chart that shows in month 1 the patients take three seperate infusions of ketamine or placebo.

They have some therapy sessions.

Then three months later they have a,face to face appointment, that's it for the test data.

They have optional 6 month and 12 month telephone follow ups.

Exeter started testing in April 2025.

There should be some updates and interviews in due course that could lead to take over offers.

More-Kare

Number of people who have started the trial: 56*

*please note this figure is not updated automatically and was last updated on 30/APR/2025

Below you will find a map detailing the different MORE-KARE sites. 8 of our sites are currently accepting people onto the trial; these are Exeter, Oxford, Kings College London, Surrey, Sussex, Manchester, and Plymouth. We are aiming to open the Imperial College London site soon, check back for updates.

How accurate is this machine learning?

The "Solvonis" timeline related to the "MORE-KARE" trial refers to the progress and timeline of a Phase 3 clinical trial led by the University of Exeter for the treatment of alcohol use disorder. This trial, officially named MORE-KARE, aims to assess the efficacy and safety of a treatment involving ketamine. The trial has closed for recruitment, according to Solvonis Therap Share Chat.

Key points of the MORE-KARE timeline:

Phase 3 Trial:

The MORE-KARE trial is a Phase 3 clinical trial, a crucial stage in the development of a new drug or treatment.

University of Exeter:

The trial is being conducted by the University of Exeter, a major research institution in the UK.

Treatment Focus:

The trial focuses on evaluating ketamine as a potential treatment for alcohol use disorder.

Funded by EME:

The trial is co-funded by the EME Programme, a partnership between the UK's National Institute for Health Research (NIHR) and the Medical Research Council (MRC).

Recruitment Closed:

The trial has now closed for recruitment, according to Solvonis Therap Share Chat.

Data Analysis and Potential Release:

The trial is currently in the data analysis phase, and the results are expected to be released in due course, potentially leading to NHS production of the product.

Awakn SP for 12 Months prior to take over.

https://finance.yahoo.com/quote/AWKNF/?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAANzHvaJQpRunvWSI_souGe0HWynHWGeFxkMQzi4GZuz8_gsD28bWDJiNtFB6uwfqa30r-TcQnJCWSxlwduVSVZtWzjC6EFabJAdgcKsbXXyvyqcQP0YyoL3xVvHmecCMl4X0eWdqEBPSxp4BoUkt7op-46LynsPccUnpbKseA62V

52 Week Range

0.0487 - 0.1334 Expressed in Canadian Dollars.

Interviewed about Sentia his Non Alcoholic spirits range.

“If everyone in the world drank Sentia or Alcarelle, there’d be 3 million fewer deaths a year from alcohol,” says Nutt, “but we’re not aspiring to that. We’re looking to have perhaps 10% of the alcohol market, which is £1 trillion a year right now.

“The main thing is to give people who like alcohol but are concerned about the possible health problems a choice. I do actually like drinking – my daughter and I own a wine bar in South Ealing – but I’d just like to have the effect of drinking with less of the harm.”

If you take the rollovers on 12,750,000 and 17,250,000 from Friday after hours and Monday first thing they would tie together quite nicely?

Note the bulk of these warrants ( 264m ) are Lenders Warrants from Awakn when N.Nelson ( Ex Chairman who gave way for Dennis Purcell ) and 1 other privately lent the business the money to formulate 001, 002 and 014, its not money spaffed on overinflated small cap salaries.